1-3 of 3
Cesar R. Gonzalez-Bonilla, MD, PhD
Close
Sort by
Journal Articles

Direct and Enhanced Cytotoxicity of the Bcl-2 Family Inhibitor GX15-070 on Rituximab-Sensitive and Rituximab-Resistant B-NHL Clones.

Melisa A. Martinez-Paniagua, McS, Mario I. Vega, PhD, Sara Huerta-Yepez, PhD, Bernardo Martinez-Miguel, Rogelio Hernandez-Pando, MD PhD, Cesar R. Gonzalez-Bonilla, MD PhD, Benjamin Bonavida, PhD
Journal: Blood
Blood (2007) 110 (11): 1402.
https://doi.org/10.1182/blood.V110.11.1402.1402
Published: 2007
Journal Articles

Rituximab Sensitizes TRAIL-Resistant B-NHL Lines to Apoptosis by Both TRAIL and Fully Humanized Antibodies Targeting TRAIL-R1 (Mapatumumab) and TRAIL-R2 (Lexatumumab).

Mario I. Vega, PhD, Sara Huerta-Yepez, PhD, Stavroula Baritaki, PhD, Melisa A. Martinez-Paniagua, McS, Cesar R. Gonzalez-Bonilla, MD, PhD, Benjamin Bonavida, PhD
Journal: Blood
Blood (2007) 110 (11): 2350.
https://doi.org/10.1182/blood.V110.11.2350.2350
Published: 2007
Journal Articles

Cytotoxicity of Genetically Engineered Fusion Protein with CD154 Peptide Mimetic (OmpC-CD154 p ) on B-NHL Cell Lines.

Bernardo Martinez-Miguel, Melisa A. Martinez-Paniagua, McS, Sara Huerta-Yepez, PhD, Rogelio Hernandez-Pando, MD PhD, Cesar R. Gonzalez-Bonilla, MD PhD, Benjamin Bonavida, PhD, Mario I. Vega, PhD
Journal: Blood
Blood (2007) 110 (11): 4525.
https://doi.org/10.1182/blood.V110.11.4525.4525
Published: 2007